FDA Officials Offer Tips On How To Improve CMC Packages To Win ANDA Approvals
This article was originally published in The Gold Sheet
Executive Summary
With FDA increasingly refusing to receive ANDAs, typically because of CMC deficiencies, agency officials recently shared some advice on how sponsors can improve their submissions.
You may also be interested in...
Pharmaceutical Industry and FDA Preparing for ICH M7 Implementation
The pharmaceutical industry is concerned about the cost involved in setting up complex computational systems required for evaluating potential genotoxic impurities in drug substances and drug products under ICH M7. The guidance goes into effect in January 2016 for drugs in clinical development and in July 2017 for new and generic drug applications as well as drugs with post-approval changes.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.